Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00605371 · ClinicalTrials.gov registry record · Phase 1
Bioequivalence and Food Effect of 250mg of Lamotrigine XR
A Phase 1 study of Epilepsy, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 209
- Enrollment target
- 1
- Study location
NCT00605371 is a Phase 1 study of Epilepsy that has completed, run by GlaxoSmithKline. The registered enrollment target is 209 participants, below the 951-participant average among 160 other Epilepsy trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00605371, a Phase 1 study of Epilepsy, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 209 participants
- Enrollment target
- 1
- Study location
Study Summary
This study intends to demonstrate bioequivalence and lack of food effect on 250mg lamotrigine XR in healthy male and female volunteers
Conditions Studied
Interventions
- DRUG Lamotrigine tablet
- DRUG Lamotrigine caplet
Study Locations (1)
Washington
- GSK Investigational Site - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 209 participants |
| Start Date | 2008-01-15 |
| Est. Completion | 2008-03-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00605371
The ClinicalTrials.gov registry entry for NCT00605371 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 209 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 951-participant average among 160 other Epilepsy trials with a reported enrollment target (78% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 2 interventions - of which Lamotrigine tablet is the first listed.
NCT00605371 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT00605371 about?
NCT00605371 is a clinical study titled "Bioequivalence and Food Effect of 250mg of Lamotrigine XR". This study intends to demonstrate bioequivalence and lack of food effect on 250mg lamotrigine XR in healthy male and female volunteers
What is the current status of trial NCT00605371?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 209 participants. The study started on 2008-01-15. Estimated completion is 2008-03-06.
What conditions does trial NCT00605371 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT00605371?
The interventions under investigation include: Lamotrigine tablet (DRUG), Lamotrigine caplet (DRUG).
Who is sponsoring clinical trial NCT00605371?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00605371 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
-
Understanding Ketamine's Dissociative Effects (KD Study)
RECRUITING · Phase 1
-
A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy
RECRUITING · Phase 1
-
A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy
RECRUITING · Phase 1
-
Microelectrode Recordings From the Vagus Nerve in Awake Humans
RECRUITING · Phase 1
-
Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.